Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H21N5O2S2 |
Molecular Weight | 331.457 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O
InChI
InChIKey=SGXXNSQHWDMGGP-WDZFZDKYSA-N
InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6-
Molecular Formula | C12H21N5O2S2 |
Molecular Weight | 331.457 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
DescriptionSources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e7e5162-a1e7-4fbe-895e-e598f5dc2bd3Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2892249
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e7e5162-a1e7-4fbe-895e-e598f5dc2bd3
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2892249
Nizatidine, chemically N-[2-[[[2- [(dimethylamino)methyl]-4-thiazolyl]methyl]thio]ethyl]-N’ -methyl-2-nitro-1,1-ethenediamine, is a histamine H2-receptor antagonist.
Nizatidine reduced gastric acid secretion for up to 8 h suggesting that this compound could be used in with a once or twice daily dosage regime. Nizatidine was rapidly and well-absorbed orally, was widely distributed in tissues and the majority of the dose was excreted in the urine within 24 h. Nizatidine is indicated for duodenal and gastric ulcer as well as for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to gastroesophageal reflux disease.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1941 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18157166 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | NIZATIDINE Approved UseNizatidine capsules USP are indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks.
Nizatidine capsules USP are indicated for maintenance therapy for duodenal ulcer patients at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. The consequences of continuous therapy with nizatidine for longer than 1 year are not known.
Nizatidine capsules USP are indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD.
Nizatidine capsules USP are indicated for up to 8 weeks for the treatment of active benign gastric ulcer. Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration. Launch Date2011 |
|||
Primary | NIZATIDINE Approved UseNizatidine capsules USP are indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks.
Nizatidine capsules USP are indicated for maintenance therapy for duodenal ulcer patients at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. The consequences of continuous therapy with nizatidine for longer than 1 year are not known.
Nizatidine capsules USP are indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD.
Nizatidine capsules USP are indicated for up to 8 weeks for the treatment of active benign gastric ulcer. Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration. Launch Date2011 |
|||
Primary | NIZATIDINE Approved UseNizatidine capsules USP are indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks.
Nizatidine capsules USP are indicated for maintenance therapy for duodenal ulcer patients at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. The consequences of continuous therapy with nizatidine for longer than 1 year are not known.
Nizatidine capsules USP are indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD.
Nizatidine capsules USP are indicated for up to 8 weeks for the treatment of active benign gastric ulcer. Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration. Launch Date2011 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1422.9 ng/mL |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
NIZATIDINE plasma | Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: UNKNOWN food status: UNKNOWN |
|
1480.2 ng/mL |
150 mg 1 times / day steady-state, oral dose: 150 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NIZATIDINE plasma | Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: UNKNOWN food status: UNKNOWN |
|
1367.6 ng/mL |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
NIZATIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3764.2 ng × h/mL |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
NIZATIDINE plasma | Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: UNKNOWN food status: UNKNOWN |
|
3776.1 ng × h/mL |
150 mg 1 times / day steady-state, oral dose: 150 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NIZATIDINE plasma | Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: UNKNOWN food status: UNKNOWN |
|
3703.1 ng × h/mL |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
NIZATIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.2 h |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
NIZATIDINE plasma | Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: UNKNOWN food status: UNKNOWN |
|
1.3 h |
150 mg 1 times / day steady-state, oral dose: 150 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NIZATIDINE plasma | Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: UNKNOWN food status: UNKNOWN |
|
1.4 h |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
NIZATIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
65% |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
NIZATIDINE plasma | Homo sapiens population: UNHEALTHY age: ADOLESCENT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
300 mg 1 times / day multiple, oral Highest studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy, adult |
Disc. AE: Peptic ulcer disease, Cough... AEs leading to discontinuation/dose reduction: Peptic ulcer disease Sources: Cough |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cough | Disc. AE | 300 mg 1 times / day multiple, oral Highest studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy, adult |
Peptic ulcer disease | Disc. AE | 300 mg 1 times / day multiple, oral Highest studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: |
unhealthy, adult |
PubMed
Title | Date | PubMed |
---|---|---|
Nizatidine-induced delirium in a nonagenarian. | 1997 Jul |
|
Effects of different antisecretory drugs on gastric potential difference in the rat: comparison with sucralfate. | 1998 Dec |
|
Effects of histamine H(2)-receptor antagonists on human plasma levels of calcitonin gene-related peptide, substance P and vasoactive intestinal peptide. | 2002 Nov |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
Patents
Sample Use Guides
Active Duodenal Ulcer: The recommended oral dosage of adults is 300 mg once daily at bedtime. An alternative dosage regimen is 150 mg twice daily.
Maintenance of Healed Duodenal Ulcer: The recommended oral dosage for adults is 150 mg once daily at bedtime.
Gastroesophageal Reflux Disease: The recommended oral dosage in adults for the treatment of erosions, ulcerations, and associated heartburn is 150 mg twice daily.
Active Benign Gastric Ulcer: The recommended oral dosage is 300 mg given either as 150 mg twice daily or 300 mg once daily at bedtime. Prior to treatment, care should be taken to exclude the possibility of malignant gastric ulceration.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9539643
In guinea pig antral muscle strips nizatidine increased the amplitude of spontaneous phasic antral contractions in a concentration-dependent fashion with threshold concentrations of 5 uM. In isolated cells, nizatidine induced concentration-dependent cell shortening, with maximal shortening at 10 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:21:15 GMT 2025
by
admin
on
Mon Mar 31 18:21:15 GMT 2025
|
Record UNII |
P41PML4GHR
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
NBK548387
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
||
|
NDF-RT |
N0000175784
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
||
|
WHO-VATC |
QA02BA04
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
||
|
NDF-RT |
N0000000151
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
||
|
NCI_THESAURUS |
C29702
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
||
|
WHO-ATC |
A02BA04
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7601
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
PRIMARY | |||
|
3574
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
PRIMARY | |||
|
Nizatidine
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
PRIMARY | |||
|
S-90
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
PRIMARY | |||
|
m8017
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
PRIMARY | Merck Index | ||
|
4513
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
PRIMARY | |||
|
D016567
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
PRIMARY | |||
|
76963-41-2
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
PRIMARY | |||
|
1955
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
PRIMARY | |||
|
7248
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
PRIMARY | |||
|
DTXSID5023376
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
PRIMARY | |||
|
SUB09335MIG
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
PRIMARY | |||
|
100000092426
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
PRIMARY | |||
|
DB00585
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
PRIMARY | |||
|
C29295
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
PRIMARY | |||
|
42319
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
PRIMARY | RxNorm | ||
|
NIZATIDINE
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
PRIMARY | |||
|
P41PML4GHR
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
PRIMARY | |||
|
1467804
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
PRIMARY | |||
|
CHEMBL653
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
PRIMARY | |||
|
759289
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
PRIMARY | |||
|
5194
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
PRIMARY | |||
|
P41PML4GHR
Created by
admin on Mon Mar 31 18:21:15 GMT 2025 , Edited by admin on Mon Mar 31 18:21:15 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
About 7% of dose
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
about 5% of dose
MINOR
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||